文献速递前列腺癌

罕见功能缺失变异与侵袭性前列腺癌及生存相关的基因鉴定

Identification of Genes with Rare Loss of Function Variants Associated with Aggressive Prostate Cancer and Survival.
PubMed 文献 · Eur Urol Oncol · 2024-03-07

基于英国遗传性前列腺癌研究六项已发表研究的汇总分析,对6805例前列腺癌病例的10个候选基因进行罕见功能缺失变异测序,发现ATM、BRCA2、MSH2和NBN与侵袭性前列腺癌相关,这些基因及MLH1的胚系突变携带者前列腺癌特异性生存期更短。

要点

  • ATM、BRCA2、MSH2和NBN的罕见功能缺失变异与侵袭性前列腺癌相关(比值比=2.67-18.9)。
  • 上述四基因及MLH1还与一个或多个次要分析表型相关。
  • 这些基因胚系突变携带者的前列腺癌特异性生存期短于非携带者(风险比=2.15,95%置信区间1.79-2.59,P=4×10⁻¹⁶)。

核心结论

  • 本研究进一步支持特定基因的罕见功能缺失变异可能增加侵袭性前列腺癌风险,并可能有助于确定用于筛查和治疗考量的信息性基因panel。

研究设计与样本

  • 对英国遗传性前列腺癌研究(UKGPCS)中六项已发表研究的罕见变异测序数据进行汇总分析,纳入6805例前列腺癌病例,所有样本均对10个候选基因进行了测序。

主要发现

  • ATM、BRCA2、MSH2和NBN的功能缺失变异与前列腺癌侵袭性相关(比值比=2.67-18.9)。
  • 上述四个基因及MLH1还与一个或多个次要分析表型相关。
  • 这些基因胚系突变携带者的前列腺癌特异性生存期短于非携带者(风险比=2.15,95%置信区间1.79-2.59,P=4×10⁻¹⁶)。

关键数值与推荐

  • 侵袭性分类定义为:前列腺癌死亡、转移性疾病、T4期、或T3期且Gleason评分≥8。

临床怎么用

  • 作者认为,特定基因的罕见功能缺失变异可能增加侵袭性前列腺癌风险,并可能有助于确定用于筛查和治疗考量的信息性基因panel。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Prostate cancer (PrCa) is a substantial cause of mortality among men globally. Rare germline mutations in BRCA2 have been validated robustly as increasing risk of aggressive forms with a poorer prognosis; however, evidence remains less definitive for other genes. OBJECTIVE: To detect genes associated with PrCa aggressiveness, through a pooled analysis of rare variant sequencing data from six previously reported studies in the UK Genetic Prostate Cancer Study (UKGPCS). DESIGN, SETTING, AND PARTICIPANTS: We accumulated a cohort of 6805 PrCa cases, in which a set of ten candidate genes had been sequenced in all samples. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: We examined the association between rare putative loss of function (pLOF) variants in each gene and aggressive classification (defined as any of death from PrCa, metastatic disease, stage T4, or both stage T3 and Gleason score ≥8). Secondary analyses examined staging phenotypes individually. Cox proportional hazards modelling and Kaplan-Meier survival analyses were used to further examine the relationship between mutation status and survival. RESULTS AND LIMITATIONS: We observed associations between PrCa aggressiveness and pLOF mutations in ATM, BRCA2, MSH2, and NBN (odds ratio = 2.67-18.9). These four genes and MLH1 were additionally associated with one or more secondary analysis phenotype. Carriers of germline mutations in these genes experienced shorter PrCa-specific survival (hazard ratio = 2.15, 95% confidence interval 1.79-2.59, p = 4 × 10-16) than noncarriers. CONCLUSIONS: This study provides further support that rare pLOF variants in specific genes are likely to increase aggressive PrCa risk and may help define the panel of informative genes for screening and treatment considerations. PATIENT SUMMARY: By combining data from several previous studies, we have been able to enhance knowledge regarding genes in which inherited mutations would be expected to increase the risk of more aggressive PrCa. This may, in the future, aid in the identification of men at an elevated risk of dying from PrCa.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Saunders EJ, Dadaev T, Brook MN, et al. Identification of Genes with Rare Loss of Function Variants Associated with Aggressive Prostate Cancer and Survival. Eur Urol Oncol. 2024. PMID: 38458890. doi:10.1016/j.euo.2024.02.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。